NASDAQ: FTRE · Biotechnology

Fortrea Holdings (FTRE) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values Fortrea Holdings (FTRE) at $24.79 a share. The stock last closed at $19.79, which puts the model's fair value 25.3% above the price. On the model's bands that reads as Undervalued.

Revalued . Price is the close of 16 Nov 2026. Fortrea Holdings Inc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$24.79midpoint of 2,000 simulations
Last close$19.79NASDAQ: FTRE
Gap to fair value+25.3%fair value against price
Model verdictUndervaluedevidence grade: Medium

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $29.96 to $24.79 (-17.3%). The model changed its method this week; the move is not broken down.

What the model makes of itThe price of $19.79 is 25.3% below it: Undervalued, on a medium evidence grade.

What's nextNext report on 25 Feb 2027. Options prices imply a move of about 20% either way over the next month. On the model's Scorecard Leaders list since 5 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give FTRE?

The calibrated range for FTRE over 63 trading days is $15.66 to $25.30. It sits around the last close, and its width comes from the volatility that FTRE's own options imply (71% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $14.52 to $38.60. In 63% of the simulations the fair value came out above the price the model ran on.

$6.22$69.38
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $24.79. Dashed line: the last close, $19.79.

Faircurve Insights · 14 Nov 2026

Fortrea Holdings Inc. (FTRE) functions as a global contract research organisation (CRO). It concentrates on development services for biopharmaceutical products and medical devices.

Faircurve's model put the fair value of Fortrea at $24.79 a share on 14 Nov 2026. This is the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $29.96, so the fair value moved -17.3%. The model changed its method this week, and the move is not broken down. The calibrated range over 63 trading days is $15.99 to $25.83. It is built around the price from the volatility the stock's own options imply, and calibrated weekly against realised prices from 8,038 past valuations. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium. The grade reflects how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.

Fortrea scores 40 out of 100 on the model's overall quality measure, against comparable companies. Balance sheet scores 0, with net debt to EBITDA at 8.61x. Profitability scores 32, with ROIC at 2.9% against a peer median of 0.1%. Growth quality scores 36, with trailing revenue growth at 1.0% against a peer median of 11.7%. The model compares Fortrea with Vericel Corporation (VCEL) and ADMA Biologics, Inc. (ADMA).

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does FTRE report earnings, and how has the stock reacted?

Fortrea Holdings's next earnings report is scheduled for 25 Feb 2027. Companies can move their dates.

On 16 Nov 2026, FTRE's 30 day implied volatility worked out to a move of about 20.5% over one month, in either direction. That is a size, not a direction.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across FTRE's last 8 reports, ignoring direction, was 12.0%.

0%10%20%30%30.1%20.9%3 Mar '25no quote10.4%6 Aug '25no quote13.6%5 Nov '25no quote3.7%26 Feb '26no quote27.7%5 May '2622.0%7.8%29 Jul '2621.7%17.7%29 Oct '2612.5%5.4%5 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in FTRE

15%20%25%30%35%5 Nov '26 report29 Oct '26 report29 Jul '26 report5 May '26 report26 Feb '26 report21% at 13 Nov '2613 Nov '2513 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 25% on 13 Nov 2025, reached 32% on 23 Oct 2026 and reads 21% on 13 Nov 2026. The marks are report dates.

How does FTRE score on business quality?

Fortrea Holdings's overall quality score is 40 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.322.9%ROIC0.1%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).63
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.361.0%Revenue growth, trailing11.7%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.660.0%Net buybacks / market value0.0%
Balance sheetNet debt to EBITDA and interest coverage.08.61xNet debt / EBITDA
StabilityDownside volatility of the EBITDA margin over the last five years.4112.7 ptsEBITDA margin downside volatility, 5y34.4 pts

How does FTRE compare with similar companies?

The companies in biotechnology closest to Fortrea Holdings in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
HRMY Harmony Biosciences Holdings, Inc.$32.96$33.93+2.9%Low evidence grade
SRPT Sarepta Therapeutics, Inc.$15.13$19.51+28.9%Low evidence grade
VIR Vir Biotechnology, Inc.$9.58$9.51-0.7%Low evidence grade
RCUS Arcus Biosciences, Inc.$16.86$16.32-3.2%Low evidence grade
INVA Innoviva, Inc.$18.49$19.11+3.4%Low evidence grade
XNCR Xencor, Inc.$35.40$35.72+0.9%Low evidence grade
VCEL Vericel Corporation$57.48$65.96+14.8%Fairly valued
ADMA ADMA Biologics, Inc.$13.47$15.96+18.5%Undervalued

What the comparable companies' multiples alone would give for FTRE, the peer-implied price, is $59.74 a share on this run. The fair value weighs that against the company's own multiple.

All biotechnology stocks ranked by gap to fair value

Fortrea Holdings at a glance

Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices.

Market value
$1.9B
Sector
Healthcare
Industry
Biotechnology
Revenue expected, next twelve months
$2.8B
Consensus revenue growth, next fiscal year
-1.7%
Analysts with estimates
7
Beta to the US market
1.73
First valued by Faircurve
11 Jul 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. FTRE was among them.

How the fair value is worked out: the model prices Fortrea Holdings on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for FTRE was $29.96. As of 14 Nov 2026 it is $24.79, a change of -17.3%. The model changed its method this week; the move is not broken down. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Fortrea Holdings's valuation

Is Fortrea Holdings stock undervalued or overvalued?

On Faircurve's model, FTRE reads as Undervalued as of 14 Nov 2026. The model's fair value is $24.79 a share against a last close of $19.79, a gap of +25.3%.

What is FTRE's fair value?

$24.79 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $14.52 to $38.60.

What price range does the model give FTRE?

$15.66 to $25.30 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Fortrea Holdings report earnings next?

The next report is scheduled for 25 Feb 2027. Companies can move their dates.

How much has FTRE moved on past earnings reports?

Across its last 8 reports the median two session move was 12.0%, ignoring direction. The largest was +27.7% around the report of 5 May 2026.

How confident is the model in this valuation?

The model's evidence grade for FTRE is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on FTRE

The model has an idea open on FTRE under Scorecard Leaders since 5 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on FTRE with their outcomes. A free account is enough.

Keep reading